Sarepta Therapeutics Inc (SRPT)

02:15 AM

Former AbbVie, Amgen exec Severino takes the reins at Sarepta - FirstWord Pharma

02:15 AM

12:37 PM

Morgan Stanley Views Sarepta CEO Transition As A ‘Positive’ – So, Why Is It Cautious On SRPT Stock In The Near Term? - Stocktwits

12:37 PM

11:45 AM

SRPT Looks 87.5% Undervalued on GF Value™ - GuruFocus

11:45 AM

11:45 AM

Capricor Therapeutics (NASDAQ:CAPR) shares tumble 67% after FDA raises concerns over Deramiocel data - TechStock²

11:45 AM

11:36 AM

Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chapter - Fierce Pharma

11:36 AM

11:32 AM

FDA staff flags data concerns about Capricor's therapy; shares plunge - Reuters

11:32 AM

11:32 AM

Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO - BioPharma Dive

11:32 AM

11:17 AM

Sarepta taps AbbVie, Tessera vet Severino to write Duchenne firm's next chaper - Fierce Pharma

11:17 AM

10:49 AM

Sarepta Names Former AbbVie Executive Michael Severino New CEO - Bloomberg

10:49 AM

10:48 AM

Sarepta names former Abbvie president as CEO as Ingram retires - Reuters

10:48 AM

10:24 AM

Sarepta names former AbbVie R&D exec Michael Severino as next CEO - BioSpace

10:24 AM

09:53 AM

Sarepta names Michael Severino, former Tessera CEO, as new chief executive - STAT

09:53 AM

09:39 AM

Cambridge biotech taps external executive to lead after Elevidys controversy - The Business Journals

09:39 AM

09:34 AM

Sarepta Therapeutics Appoints Michael Severino as CEO - TipRanks

09:34 AM

09:27 AM

Sarepta names Michael Severino as new CEO, Ingram retires - Investing.com

09:27 AM

09:25 AM

Sarepta Therapeutics Inc (SRPT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

09:25 AM

09:22 AM

Why is Sarepta Therapeutics stock climbing today? By Investing.com - Investing.com Canada

09:22 AM

09:13 AM

Sarepta Therapeutics (SRPT) Appoints New CEO, Shares Surge 7% - GuruFocus

09:13 AM

08:30 AM

Sarepta Therapeutics Appoints Michael Severino, M.D., Chief Executive Officer - Business Wire

08:30 AM

08:26 AM

How (SRPT) Movements Inform Risk Allocation Models - Stock Traders Daily

08:26 AM

Jul 26, 2026

Sarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - Stocktwits

Jul 26, 2026

Jul 26, 2026

Sarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - Stocktwits

Jul 26, 2026

Jul 25, 2026

SRPT|Sarepta Therapeutics Inc|Price:15.680|Chg%:-0.200 - TradingKey

Jul 25, 2026

Jul 25, 2026

Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits

Jul 25, 2026

Jul 25, 2026

Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits

Jul 25, 2026

Jul 25, 2026

SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space - Stocktwits

Jul 25, 2026

Jul 25, 2026

SRPT Stock Plunges 7% After-Hours As Elevidys Demand Slumps — CEO Still Sees Return To Growth - Stocktwits

Jul 25, 2026

Jul 24, 2026

SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits

Jul 24, 2026

Jul 24, 2026

Sarepta Therapeutics Market Sentiment - Benzinga España

Jul 24, 2026

Jul 24, 2026

Skorney: FDA's Sarepta Precedent Makes Dyne DMD Approval 'Impossible' to Deny - finance.biggo.com

Jul 24, 2026

Jul 24, 2026

Sarepta Therapeutics, Inc. Revenue Breakdown – NASDAQ:SRPT - TradingView

Jul 24, 2026

Jul 24, 2026

Sarepta Therapeutics Inc (SRPT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

Jul 24, 2026

Jul 23, 2026

Sarepta Therapeutics stock steadies as investors weigh Elevidys expansion and revenue trajectory - Ad-hoc-news.de

Jul 23, 2026

Jul 22, 2026

SRPT: Sarepta Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits

Jul 22, 2026

Jul 22, 2026

Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results - Finviz

Jul 22, 2026

Jul 22, 2026

SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat? - The Globe and Mail

Jul 22, 2026

Jul 22, 2026

Press Release: Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results - Moomoo

Jul 22, 2026

Jul 21, 2026

Sarepta Therapeutics Stock Short Interest Rises to 32.62% - Quiver Quantitative

Jul 21, 2026

Jul 20, 2026

Sarepta Therapeutics, Inc. (SRPT) Stock Analysis: Exploring a 28.77% Potential Upside for Investors - DirectorsTalk Interviews

Jul 20, 2026

Jul 18, 2026

Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress? - Sahm

Jul 18, 2026

Jul 17, 2026

uniQure Trends to Watch as Gene Therapy Bets Shift Beyond Hemgenix - TradingView

Jul 17, 2026

Jul 15, 2026

This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next - Stocktwits

Jul 15, 2026

Jul 15, 2026

Trading Systems Reacting to (SRPT) Volatility - Stock Traders Daily

Jul 15, 2026

Jul 15, 2026

SRPT Stock Clocks Highest Daily Gain In Nearly 8 Years After Rare Muscle Disorders Study Data But Wall Street's Not Wholly Convinced - Stocktwits

Jul 15, 2026

Jul 14, 2026

Sarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Jul 14, 2026

Jul 14, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Sarepta Therapeutics, Inc. (SRPT) - Supply Chain Digital

Jul 14, 2026

Jul 14, 2026

Is Sarepta Therapeutics (SRPT) Undervalued Following FDA Progress On AMONDYS 45 And VYONDYS 53? - Sahm

Jul 14, 2026

Jul 13, 2026

Following FDA sNDA Acceptance Is Sarepta Therapeutics (SRPT) Still Undervalued? - Yahoo Finance

Jul 13, 2026

Jul 13, 2026

The Bull Case For Sarepta Therapeutics (SRPT) Could Change Following FDA sNDA Acceptance On DMD Therapies - Yahoo Finance

Jul 13, 2026

Jul 13, 2026

Sarepta Therapeutics (SRPT) Stock Analysis: Evaluating a 16.53% Potential Upside Amidst a Volatile Biotech Landscape - DirectorsTalk Interviews

Jul 13, 2026

Jul 11, 2026

2 Beaten-Down Stocks That Still Aren't Worth Buying - The Motley Fool

Jul 11, 2026